vs
Side-by-side financial comparison of El Pollo Loco Holdings, Inc. (LOCO) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $126.2M, roughly 1.3× El Pollo Loco Holdings, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 6.5%, a 64.7% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 5.9%).
El Pollo Loco, Inc., is a restaurant chain based in the United States, specializing in Mexican-style grilled chicken. Restaurant service consists of dine-in and take-out, with some locations offering drive-through options. The company is headquartered in Costa Mesa, California, and operates about 500 company-owned and franchised restaurants in the Southwestern United States.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
LOCO vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $126.2M | $158.6M |
| Net Profit | $8.2M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 9.7% | 70.2% |
| Net Margin | 6.5% | 71.2% |
| Revenue YoY | 5.9% | 3661.1% |
| Net Profit YoY | 48.8% | 528.0% |
| EPS (diluted) | $0.27 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $126.2M | — | ||
| Q4 25 | $123.5M | — | ||
| Q3 25 | $121.5M | — | ||
| Q2 25 | $125.8M | — | ||
| Q1 25 | $119.2M | $158.6M | ||
| Q4 24 | $114.3M | $22.6M | ||
| Q3 24 | $120.4M | — | ||
| Q2 24 | $122.2M | — |
| Q1 26 | $8.2M | — | ||
| Q4 25 | $6.5M | — | ||
| Q3 25 | $7.4M | — | ||
| Q2 25 | $7.1M | — | ||
| Q1 25 | $5.5M | $112.9M | ||
| Q4 24 | $6.0M | $-10.5M | ||
| Q3 24 | $6.2M | — | ||
| Q2 24 | $7.6M | — |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 8.3% | — | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 9.0% | — | ||
| Q1 25 | 7.5% | 70.2% | ||
| Q4 24 | 7.9% | -60.4% | ||
| Q3 24 | 8.4% | — | ||
| Q2 24 | 10.1% | — |
| Q1 26 | 6.5% | — | ||
| Q4 25 | 5.3% | — | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | 5.6% | — | ||
| Q1 25 | 4.6% | 71.2% | ||
| Q4 24 | 5.2% | -46.4% | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 6.2% | — |
| Q1 26 | $0.27 | — | ||
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.25 | — | ||
| Q2 25 | $0.24 | — | ||
| Q1 25 | $0.19 | $1.90 | ||
| Q4 24 | $0.21 | $-0.15 | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.9M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $302.5M | $350.1M |
| Total Assets | $609.1M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.9M | — | ||
| Q4 25 | $6.2M | — | ||
| Q3 25 | $10.9M | — | ||
| Q2 25 | $9.0M | — | ||
| Q1 25 | $4.3M | $274.8M | ||
| Q4 24 | $2.5M | $128.0M | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $10.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | $51.0M | — | ||
| Q3 25 | $61.0M | — | ||
| Q2 25 | $69.0M | — | ||
| Q1 25 | $73.0M | — | ||
| Q4 24 | $71.0M | — | ||
| Q3 24 | $76.0M | — | ||
| Q2 24 | $87.0M | — |
| Q1 26 | $302.5M | — | ||
| Q4 25 | $291.1M | — | ||
| Q3 25 | $282.9M | — | ||
| Q2 25 | $274.2M | — | ||
| Q1 25 | $265.7M | $350.1M | ||
| Q4 24 | $260.7M | $229.0M | ||
| Q3 24 | $255.2M | — | ||
| Q2 24 | $248.6M | — |
| Q1 26 | $609.1M | — | ||
| Q4 25 | $606.6M | — | ||
| Q3 25 | $602.7M | — | ||
| Q2 25 | $596.8M | — | ||
| Q1 25 | $590.5M | $406.9M | ||
| Q4 24 | $592.0M | $271.6M | ||
| Q3 24 | $590.0M | — | ||
| Q2 24 | $593.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.18× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $13.9M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $4.7M | $131.8M | ||
| Q4 24 | $5.6M | $-23.2M | ||
| Q3 24 | $13.0M | — | ||
| Q2 24 | $17.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $5.1M | — | ||
| Q3 25 | $9.9M | — | ||
| Q2 25 | $9.1M | — | ||
| Q1 25 | $1.3M | $131.7M | ||
| Q4 24 | $1.1M | $-23.2M | ||
| Q3 24 | $9.1M | — | ||
| Q2 24 | $10.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | — | ||
| Q3 25 | 8.2% | — | ||
| Q2 25 | 7.2% | — | ||
| Q1 25 | 1.1% | 83.0% | ||
| Q4 24 | 1.0% | -102.7% | ||
| Q3 24 | 7.6% | — | ||
| Q2 24 | 8.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.1% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 2.8% | 0.1% | ||
| Q4 24 | 3.9% | 0.2% | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 5.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.13× | — | ||
| Q3 25 | 2.08× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 0.86× | 1.17× | ||
| Q4 24 | 0.95× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 2.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
